Refractory AML

17 clinical trials · Condition

Record	Firm	Date
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia (NCT05226468)	New Epsilon Innovation Limited	2022-04-25
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE (NCT05193448)	French Innovative Leukemia Organisation	2021-07-05
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) (NCT04330820)	Technische Universität Dresden	2020-04-06
Natural Killer Cell (CYNK-001) Infusions in Adults with AML (NCT04310592)	Celularity Incorporated	2020-03-12
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03850574)	Aptose Biosciences Inc.	2019-03-11
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia (NCT03516760)	AvenCell Europe GmbH	2018-04-11
Phase 1 Study of Quizartinib (NCT02675478)	Daiichi Sankyo Co., Ltd.	2016-02-01

Every clearance here is in the API, with alerts when new ones post.